|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
13
|
|
pubmed:dateCreated |
2007-4-3
|
|
pubmed:abstractText |
We previously reported that the fixed-dose combination of isosorbide dinitrate and hydralazine hydrochloride (FDC I/H) significantly decreased the risk of all-cause death and first hospitalization for heart failure (HF) and improved quality of life in patients with New York Heart Association class III or IV heart failure in the African-American Heart Failure Trial (A-HeFT). The current analyses further define the effect of FDC I/H on the timing of event-free survival (mortality or first hospitalization for HF) and time to first hospitalization for HF, as well as effects by subgroups and effects on cause-specific mortality.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1524-4539
|
|
pubmed:author |
pubmed-author:AdamsKirkwoodK,
pubmed-author:African-American Heart Failure Trial Investigators,
pubmed-author:COEM RMR,
pubmed-author:CarsonPeterP,
pubmed-author:CohnJay NJN,
pubmed-author:FerdinandKeithK,
pubmed-author:OfiliElizabethE,
pubmed-author:OlukotunAdeoye YAY,
pubmed-author:SabolinskiMichael LML,
pubmed-author:TamS WilliamSW,
pubmed-author:TaylorAnne LAL,
pubmed-author:WorcelManuelM,
pubmed-author:YancyClyde WCW,
pubmed-author:ZiescheSusanS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
3
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1747-53
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17372175-Adult,
pubmed-meshheading:17372175-African Americans,
pubmed-meshheading:17372175-Aged,
pubmed-meshheading:17372175-Arthralgia,
pubmed-meshheading:17372175-Biological Markers,
pubmed-meshheading:17372175-Cardiovascular Agents,
pubmed-meshheading:17372175-Cause of Death,
pubmed-meshheading:17372175-Disease-Free Survival,
pubmed-meshheading:17372175-Dizziness,
pubmed-meshheading:17372175-Double-Blind Method,
pubmed-meshheading:17372175-Drug Combinations,
pubmed-meshheading:17372175-Heart Failure,
pubmed-meshheading:17372175-Heart Transplantation,
pubmed-meshheading:17372175-Hospitalization,
pubmed-meshheading:17372175-Humans,
pubmed-meshheading:17372175-Hydralazine,
pubmed-meshheading:17372175-Hypotension,
pubmed-meshheading:17372175-Isosorbide Dinitrate,
pubmed-meshheading:17372175-Kaplan-Meier Estimate,
pubmed-meshheading:17372175-Middle Aged,
pubmed-meshheading:17372175-Mortality,
pubmed-meshheading:17372175-Natriuretic Peptide, Brain,
pubmed-meshheading:17372175-Nitric Oxide Donors,
pubmed-meshheading:17372175-Proportional Hazards Models,
pubmed-meshheading:17372175-Quality of Life,
pubmed-meshheading:17372175-Questionnaires,
pubmed-meshheading:17372175-Treatment Outcome,
pubmed-meshheading:17372175-Vasodilator Agents
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
|
|
pubmed:affiliation |
Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
